About Abeecare

Abeecare (Abiraterone) is a medication used to manage advanced prostate cancer by targeting key processes that fuel the growth of the cancer. It works by inhibiting an enzyme called CYP17A1, which is crucial in the production of androgens like testosterone. These hormones play a major role in the growth of prostate cancer. By blocking CYP17A1, Abiraterone reduces the levels of these hormones, which helps slow or stop the cancer cells from growing and spreading.

Abiraterone is especially effective in cases of metastatic castration-resistant prostate cancer (CRPC) and hormone-sensitive high-risk metastatic prostate cancer. It works by blocking a key step in androgen biosynthesis, preventing the production of testosterone and other androgens in the adrenal glands and prostate tumor tissues. This helps limit cancer cell growth. In addition to reducing androgen production, Abiraterone also prevents androgen receptor activation, further slowing cancer progression. It has been shown in lab studies and animal models to significantly reduce cancer cell proliferation and slow tumor growth, making it an important option for patients whose cancer has become resistant to other treatments.